While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.
Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.
In June, 23andMe (NASDAQ: ME) officially finished the process of going public via a special purpose acquisition company (SPAC). While no one knows where shares of the genetic-testing company will trade in the near term, investors have a better idea of where 23andMe stock can trade over the long term. Over the course of years, stock prices tend to correlate with cash flows and, therefore, if the company dramatically increases it cash flows, the stock price could head higher as well.